IRIS
MUSOLINO, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.401
AS - Asia 4.381
EU - Europa 2.790
SA - Sud America 803
AF - Africa 291
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 5
Totale 12.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.255
SG - Singapore 2.245
CN - Cina 1.054
IE - Irlanda 829
BR - Brasile 653
HK - Hong Kong 477
IT - Italia 395
SE - Svezia 393
DE - Germania 344
VN - Vietnam 292
NL - Olanda 214
ZA - Sudafrica 208
FI - Finlandia 111
CA - Canada 89
GB - Regno Unito 84
RU - Federazione Russa 80
UA - Ucraina 71
IN - India 70
AR - Argentina 64
AT - Austria 63
FR - Francia 55
BD - Bangladesh 36
BE - Belgio 35
CI - Costa d'Avorio 33
PL - Polonia 32
TR - Turchia 31
MX - Messico 29
IQ - Iraq 25
EC - Ecuador 24
ES - Italia 24
JP - Giappone 20
ID - Indonesia 19
KR - Corea 17
A1 - Anonimo 16
CL - Cile 15
UZ - Uzbekistan 15
PK - Pakistan 14
CO - Colombia 12
MA - Marocco 12
CZ - Repubblica Ceca 11
LT - Lituania 10
PY - Paraguay 10
VE - Venezuela 10
UY - Uruguay 9
KE - Kenya 8
SA - Arabia Saudita 8
IL - Israele 7
IR - Iran 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
EG - Egitto 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
HR - Croazia 5
MY - Malesia 5
NI - Nicaragua 5
RO - Romania 5
EU - Europa 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AU - Australia 3
CH - Svizzera 3
HN - Honduras 3
JM - Giamaica 3
JO - Giordania 3
LK - Sri Lanka 3
NG - Nigeria 3
PA - Panama 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
GH - Ghana 2
GT - Guatemala 2
HU - Ungheria 2
IS - Islanda 2
LV - Lettonia 2
MK - Macedonia 2
NA - Namibia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
ET - Etiopia 1
GP - Guadalupe 1
GR - Grecia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
Totale 12.681
Salva come PNG Salva come JPEG
Città #
Singapore 1.112
Dublin 813
Chandler 663
Ashburn 635
Hong Kong 475
Beijing 451
Santa Clara 366
Dallas 209
Boardman 206
Johannesburg 196
Princeton 147
Ann Arbor 140
Shanghai 113
New York 110
Ho Chi Minh City 108
Bremen 104
Los Angeles 85
Des Moines 80
Helsinki 72
Hanoi 66
Munich 62
Parma 61
Jacksonville 60
Seattle 60
Grafing 57
Moscow 55
Wilmington 55
São Paulo 54
Vienna 52
Montreal 45
Hefei 42
Milan 41
Columbus 37
Abidjan 33
Dearborn 32
Buffalo 29
Nuremberg 29
Brussels 28
Nanjing 25
Rio de Janeiro 25
Bologna 22
San Mateo 22
Toronto 21
Brooklyn 20
Frankfurt am Main 20
The Dalles 20
Shenyang 19
Stockholm 19
Phoenix 18
Warsaw 18
Jinan 17
Tokyo 17
Belo Horizonte 16
Haiphong 15
Rome 15
Woodbridge 15
Fairfield 14
Tashkent 14
Boston 13
Curitiba 13
London 13
Pune 13
Tianjin 13
Ardea 12
Brasília 12
Changsha 12
Chicago 12
Rio Saliceto 12
Amsterdam 11
Atlanta 11
Denver 11
Fremont 11
Salvador 11
Borås 10
Campinas 10
Poplar 10
Turku 10
Buenos Aires 9
Charlotte 9
Council Bluffs 9
Houston 9
Izmir 9
Jakarta 9
Manchester 9
Montevideo 9
Nanchang 9
Ravenna 9
Reggio Emilia 9
Seoul 9
Augusta 8
Baghdad 8
Da Nang 8
Hebei 8
Rockville 8
San Francisco 8
Taiyuan 8
Dhaka 7
Falls Church 7
Hải Dương 7
Kunming 7
Totale 7.767
Salva come PNG Salva come JPEG
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 255
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 130
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 129
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 128
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 128
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 125
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 123
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 123
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 121
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 120
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 120
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 120
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 120
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 118
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 116
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 116
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 115
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 115
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 113
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 112
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 112
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 110
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 110
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 109
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 109
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 107
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 105
p73 and p53 pathway in human breast cancers. 105
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 103
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 100
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 100
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 97
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 96
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 96
A review of immune checkpoint blockade in breast cancer 96
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 95
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 95
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 94
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 94
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 94
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 94
My best choice after a round trip from illness 94
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 93
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 89
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 89
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 88
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 88
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 88
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 87
In reply 86
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 85
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 85
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 84
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 84
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 84
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 83
A narrative review of the principal glucocorticoids employed in cancer 83
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 81
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 81
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 81
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 81
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 80
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 79
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 77
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 77
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 77
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 77
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 76
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 76
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 75
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 75
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 75
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 74
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 74
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 73
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 73
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 72
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 70
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 70
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 69
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) 69
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 69
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 69
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 69
Role of Fcγ receptors in HER2-targeted breast cancer therapy 69
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 68
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 68
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 67
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 66
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 64
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy 63
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 62
DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC) 62
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 61
https://researchopenworld.com/at-doctor-level/# 61
Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFRexpressing metastatic colorectal cancer patients treated with cetuximab based therapy 61
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 60
Reply to Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large BCell NonHodgkin Lymphoma 60
BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation 60
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 59
Totale 9.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.867
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.867
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021273 0 0 0 0 0 25 43 35 68 12 70 20
2021/2022622 23 11 24 28 16 67 32 42 41 26 26 286
2022/20232.642 318 194 127 176 258 253 16 183 944 21 120 32
2023/20241.085 52 110 16 32 96 221 106 116 39 79 64 154
2024/20253.503 68 208 284 170 388 312 89 113 470 382 292 727
2025/20263.899 657 752 896 578 971 45 0 0 0 0 0 0
Totale 12.944